Ichiro Morioka, MD, PhD

Nihon University Itabashi Hospital
Tokyo, Tokyo, Japan

Disclosure(s): AstraZeneca K.K.: Honoraria; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Honoraria, Princial Investigator for MSD; Mitsubishi Tanabe Pharma Corporation: Honoraria; Pfizer Japan Inc.: Honoraria; Sanofi K.K.: Honoraria; Shino-Test Corporation: Grant/Research Support

Presentation(s):

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT